Author: healthprofessionalradio

Catherine Bornbaum, PhD, MBA, Head of Clinical Operations and Partnerships at RetiSpec discusses using hyperspectral retinal imaging and artificial intelligence to diagnose Alzheimer’s disease before the onset of symptoms. RetiSpec’s proprietary technology integrates seamlessly with an optometrist’s camera creating a new workflow from optometrist to neurologist. It provides a whole picture of disease diagnosis, is much cheaper than current methods, noninvasive, and will be of great value to Pharma as they rely on early diagnosis to recruit patients for Alzheimer’s clinical trials. 

David Drapkin, LCSW, discusses Vital, a holistic, immersive, 12-month program launched by Psychedelics Today that is designed for medical professionals, psychotherapists, and health practitioners incorporating psychedelics into their existing practices. The program is delivered and developed with world-leading academic and clinical researchers, therapists, and physicians.​ ​As a thought leader in the field of behavioral health and psychedelic therapy, David envisions a future where psychedelics play a central role in redefining true wellness.

Dr. Ran Anbar, MD, FAAP, leading expert in clinical hypnosis and Psychology Today contributor discusses clinical hypnosis, history, and misconceptions. He talks about the successful treatment of children he has personally helped that were suffering from anxiety, pain, seizures, asthma, and other illnesses. He also talks about why children especially benefit from this type of therapy and the many ways families can incorporate the logic of hypnosis concepts into their interactions and relationships on a daily basis. He has a new book titled “Changing Children’s Lives with Hypnosis: A Journey to the Center.” (Nov 2021)

Dr. Ran Anbar, MD, FAAP, a leading expert in clinical hypnosis and Psychology Today contributor discusses clinical hypnosis and what kind of medical and emotional conditions this type of therapy can help treat. He talks about the history of clinical hypnosis​, ​the misconceptions surrounding it​, ​what interested him initially in this field​,​ and how he has incorporated it into his medical practice.

President Biden recently announced a multi-faceted cancer pledge with the goal of reducing mortality from the disease by 50 percent during the next 25 years. Dr. Milan Radovich, Senior Vice President and Chief Precision Medicine Officer at Caris Life Sciences ® discusses precision medicine and why some treatments work well in some patients and not others with the same diagnosis. He talks about the lack of strategies to develop treatments for some cancers and not targeting the right treatments to the right patients; how to apply comprehensive molecular and clinical insights to help identify effective therapies; and why innovations such as liquid (blood) biopsy are charting the future of early disease detection and diagnosis. 

Dr. Emily Paul, ​a molecular biologist with a specialty in genetics and ​Product Director for SOHPiA GENETICS DDMTM discusses processing thousands of genomic profiles for diseases, such as cancer and inherited disorders, where combining genomic and phenotypic information is vital to support discoveries, treatment decisions, and drug development efforts. She talks about how researchers and HCPs can work together by sharing and leveraging patterns identified via AI and machine learning, which improves as it analyzes more data over time.​ 

Dr. Terence Rooney, Vice President, Rheumatology & Maternal-Fetal Immunology Disease Area Leader at Janssen discusses Janssen’s announcement of a comprehensive Network Meta-Analysis (NMA) at Maui Dermatology which concluded that TREMFYA ® (guselkumab) ranked highest for the overall level of skin clearance and showed positive joint efficacy among all advanced therapies approved for the treatment of active psoriatic arthritis (PsA). He talks about what this new data means for patients and why understanding the landscape of treatment options in active PsA is important for physicians making decisions about patient care. 

Craig Parker, President and CEO of Surrozen, a biotechnology company discusses how the company is discovering and developing drug candidates to selectively modulate the Wnt (Wingless/Integrated) pathway. He talks about the tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with potential application across multiple disease areas, including inflammatory bowel disease, hepatitis, eye diseases, hearing loss, lung and airway diseases, and certain neurological disorders. He also shares some of the company’s key milestones for 2022. 

Jeff Bova, Chief Commercial Officer at UroGen Pharma discusses the launch of their first FDA-approved treatment, the only non-surgical option for patients with low-grade upper tract urothelial carcinoma, or LG-UTUC. This is the first of UroGen medicines to demonstrate an industry-leading move towards more innovative, non-surgical options for patients.  He shares UroGen’s vision to fundamentally change the treatment model for some of the most devastating cancers by delivering better medicines to patients in ways never done before.